Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,138 recruiting studies in this area right now.
By phase
- Not applicable9,499
- Phase 24,397
- Phase 12,659
- Phase 1/Phase 21,650
- Phase 31,390
- Phase 2/Phase 3283
- Phase 4260
Top conditions
- Breast Cancer1,193
- Prostate Cancer646
- Cancer634
- Colorectal Cancer479
- Lung Cancer416
- Ovarian Cancer337
- Multiple Myeloma328
- Pancreatic Cancer287
- Gastric Cancer282
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer205
- Advanced Solid Tumors201
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University303
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca135
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,408
- Texas635
- Arizona513
- Florida432
- Alabama427
- New York406
- Massachusetts342
- Maryland330
- New Jersey269
- Pennsylvania235
Recruiting studies20,138 total
- NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT06317558Recruiting
Real-world study of immunotherapy before surgery for lung cancer
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
Beijing, Beijing MunicipalityAges 18–85 - NCT06339060RecruitingPhase 3
Chemoradiation and immunotherapy to save the esophagus
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
ShanghaiAges 18–75 - NCT06298968RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06485544RecruitingPhase 2
Immunotherapy before surgery for small cell lung cancer
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Xi'an, ShannxiAges 18–75 - NCT06483347RecruitingPhase 2
Immunotherapy combo for inoperable lung cancer
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05549024RecruitingEarly Phase 1
PET/CT scan study for certain prostate, brain, or breast cancers
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
BeijingAges 18 years+ - NCT06466902Recruiting
Using photos to check lymph node removal in stomach cancer surgery
This study tests if taking photos during minimally invasive stomach cancer surgery can help doctors check that all the right lymph nodes were removed. If you're having a laparoscopic or robotic gastrectomy for stomach cancer, this study might be for you.
Cremona, CRAges 18 years+ - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06301165RecruitingPhase 2
Chemotherapy comparison for advanced nasopharyngeal cancer
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
Guangzhou, GuangdongAges 18–65 - NCT05636787RecruitingPhase 2
Treosulfan chemo for myeloma before stem cell transplant
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
BernAges 18–75 - NCT06267378Recruiting
Frailty and its effects on older patients having major gut surgery
This study looks at how frailty affects recovery and outcomes for patients aged 70 and older who are having planned surgery to remove colorectal cancer. The goal is to better understand frailty's impact so care can be improved.
Doncaster, South YorkshireAges 18 years+ - NCT06490211Recruiting
Studying multi-omics data for urinary tumor diagnosis and treatment
This trial collects and analyzes imaging, lab tests, and tissue samples from people with bladder, kidney, or prostate cancer. The goal is to see how combining these different types of information can improve diagnosis and treatment decisions.
Wuhan, HubeiAges 18 years+ - NCT06313567RecruitingPhase 3
Metronomic capecitabine for stage III stomach cancer
This trial tests a low-dose, frequent regimen of the chemotherapy drug capecitabine (taken as a pill) to see if it can help prevent stage III stomach cancer from coming back after surgery. It's for people who have had their stomach cancer completely removed with a specific type of lymph node dissection.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06487429RecruitingPhase 2
Short radiation followed by combo therapy for HER2+ stomach cancer
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT06491056Recruiting
Focal therapy study for prostate cancer in Asia
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
SingaporeAges 40–85 - NCT07809256RecruitingPhase 3
Combination treatment for advanced lung cancer with a RET gene change
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
Saint PetersburgAges 18 years+ - NCT07815392Recruiting
Frailty and recovery after gastrointestinal cancer surgery
This study looks at how frailty, or overall physical weakness, affects recovery after surgery for gastrointestinal cancer in people aged 60 and older. The findings may help doctors better prepare patients for surgery and improve their recovery.
Van, VanAges 60 years+ - NCT07813637RecruitingPhase 1
Testing a combination of two new drugs for advanced prostate cancer
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT07815665RecruitingPhase 2/Phase 3
Ivonescimab plus enfortumab vedotin for advanced bladder cancer
This study compares two drug combinations for advanced bladder cancer that has spread or cannot be removed with surgery. The drugs aim to help the immune system fight the cancer more effectively.
Phoenix, ArizonaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,138 recruiting oncology studies from the U.S. registry right now, out of 29,973 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.